/
Company Overview We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men s health and oncology. Through our acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Un…
The business is unprofitable at the operating level (-2190.03% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 67.7% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$10M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$735K
▼ -67.7% YoY
Net Income (TTM)
-$10M
▲ +76.1% YoY
Op. Margin
-2109.88%
▲ +47.9pp YoY
ROIC
-106.44%
▲ +233.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +8.0% YoY
Op. Cash Flow (TTM)
-$10M
▲ +7.8% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$4M
Continue Research